• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Michael Kolodziej Remarks Upon the Difficulty of Creating Payment Models for Oncology

Video

Implementing new payment models is really complicated, and the private sector is not doing as much as the public sector, said Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc.

Implementing new payment models is really complicated, and the private sector is not doing as much as the public sector, said Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc.

Transcript

As the government is trying out a number of different payment models, what is happening in the private sector? Are we seeing any clear successes among commercial payers?

What’s happening with the commercial payers is absolutely maddening, not a darn thing. I was very proud of the program I built at Aetna and I highly commend Roger Brito and his team for continuing to work on that project and refine it. But man, it’s kind of disappointing. It’s not that I don’t understand it. I think they’re waiting to see what happens with all this stuff that Washington is doing. Implementing those kind of programs is really complicated. It takes a lot of manpower and it takes a lot of, well, let’s just say intestinal fortitude to develop an enterprise-wide strategy for oncology, and not much has happened, I think. But we’ll see.

Related Videos
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Michael Morse, MD, Duke Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.